<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735644</url>
  </required_header>
  <id_info>
    <org_study_id>JEC02</org_study_id>
    <nct_id>NCT00735644</nct_id>
  </id_info>
  <brief_title>Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines</brief_title>
  <official_title>Lot-to-lot Consistency, Bridging, and Safety Trial of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in
      toddlers aged 12-18 months.

      Primary objective:

      To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi
      pasteur.

      Secondary objective:

      To describe the safety of vaccination in all subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III trial in toddlers in Thailand and the Philippines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt;10 1/dil and post-vaccination titer ≥ 10 1/dil, or participants with pre-vaccination titer ≥ 10 1/dil and 4-fold increase from pre- to post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or Walter Reed Army Institute of Research (WRAIR) JE-CV</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Anti-Japanese Encephalitis Chimeric Virus antibodies were measured using the 50% plaque reduction neutralization test (PRNT50) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection to Japanese Encephalitis Chimeric Virus Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or WRAIR JE-CV</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the PRNT50 assay. Seroprotection was defined as the proportion of subjects with a JE CV virus PRNT50 neutralizing antibody titer ≥10 1/dilution (dil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Ratios Against the Japanese Encephalitis Chimeric Virus (JE-CV) Antigen Following Vaccination With One of the JE-CV by GPO MBP Lots or WRAIR JE-CV Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Anti Japanese encephalitis chimeric virus antibodies were measured using the PRNT50 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE- CV) by GPO MBP Lot or WRAIR JE-CV, or Hepatitis A Vaccine.</measure>
    <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
    <description>Solicited injection site: Tenderness, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Tenderness, cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling ≥5 cm. Grade 3 systemic reactions: Fever, temperature &gt;39.5˚C; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal, &gt;3 hours; Drowsiness, sleeping most of the time or difficult to wake up; Appetite Lost, refuses ≥3 or most feeds/meals; and Irritability, inconsolable.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serological Status of Flavivirus Infection at Baseline (Before) Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) or Hepatitis A Vaccine.</measure>
    <time_frame>Day 0 (pre-vaccination)</time_frame>
    <description>Flavivirus (FV) positive was defined as anti-JE against homologous virus strain ≥10 l/dil or anti dengue against at least one serotype ≥10 l/dil. FV negative was defined as anti-JE against homologous virus strain &lt;10 l/dil and anti-dengue against the 4 serotypes &lt;10 l/dilution.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>JE-CV GPO MBP (Lot 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-CV GPO MBP (Lot 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-CV GPO MBP (Lot 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-CV WRAIR (Group 4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A (Group 5)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>JE-CV GPO MBP (Lot 1)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>JE-CV GPO MBP (Lot 2)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>JE-CV GPO MBP (Lot 3)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine (Acambis)</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>JE-CV WRAIR (Group 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Hepatitis A (Group 5)</arm_group_label>
    <other_name>Avaxim® 80U Pediatric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 12 to 18 months on the day of inclusion.

          -  In good general health, without significant medical history.

          -  Provision of informed consent form signed by at least one parent or other legally
             acceptable representative, and by at least one independent witness if required by
             local regulations.

          -  Subject and parent/legally acceptable representative able to attend all scheduled
             visits and comply with all trial procedures.

          -  Completion of vaccinations according to the national immunization schedule.

        Exclusion Criteria :

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy.

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to a vaccine containing any of the same substances.

          -  Chronic illness at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator.

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of the immune response.

          -  Administration of any anti-viral within 2 months preceding V01.

          -  History of central nervous system disorder or disease, including seizures.

          -  Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination.

          -  Personal human immunodeficiency virus seropositivity in the blood sample taken at
             screening.

          -  Receipt of any JE vaccine or hepatitis A vaccine.

          -  Previous vaccination against flavivirus disease.

          -  History of flavivirus infection (confirmed either clinically, serologically or
             microbiologically)

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating intramuscular vaccination.

          -  Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on
             the day of vaccination, according to Investigator judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alabang</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bayanan</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buli</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cupang</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sucat</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother. 2012 Jul;8(7):929-37. doi: 10.4161/hv.20071. Epub 2012 Jul 1.</citation>
    <PMID>22777096</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonaparte M, Dweik B, Feroldi E, Meric C, Bouckenooghe A, Hildreth S, Hu B, Yoksan S, Boaz M. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis. 2014 Mar 21;14:156. doi: 10.1186/1471-2334-14-156.</citation>
    <PMID>24656175</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese encephalitis, Hepatitis A, Inactivated Mouse-Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 02 August 2008 through 27 March 2009 at 3 clinic sites in Thailand and 5 clinic sites in the Philippines.</recruitment_details>
      <pre_assignment_details>A total of 1200 participants who met all of the inclusion and none of the exclusion criteria were randomized, 1199 were vaccinated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JE-CV GPO MBP (Lot 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.</description>
        </group>
        <group group_id="P2">
          <title>JE-CV GPO MBP (Lot 2)</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
        </group>
        <group group_id="P3">
          <title>JE-CV GPO MBP (Lot 3)</title>
          <description>Participants 12 to 18 months of age received one dose of JE- CV from GPO MBP Lot 3</description>
        </group>
        <group group_id="P4">
          <title>JE-CV WRAIR</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
        </group>
        <group group_id="P5">
          <title>Hepatitis A</title>
          <description>Participants 12 to 18 months of age received the Hepatitis A vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="296"/>
                <participants group_id="P4" count="199"/>
                <participants group_id="P5" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="298"/>
                <participants group_id="P3" count="295"/>
                <participants group_id="P4" count="198"/>
                <participants group_id="P5" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive study vaccine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population represents the participants who have received the trial vaccine or control vaccine (safety analysis set). Data on participants were analyzed and presented according to the vaccine they actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>JE CV GPO MBP (Lot 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1 subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>JE-CV GPO MBP (Lot 2)</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
        </group>
        <group group_id="B3">
          <title>JE-CV GPO MBP (Lot 3)</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
        </group>
        <group group_id="B4">
          <title>JE-CV WRAIR</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
        </group>
        <group group_id="B5">
          <title>Hepatitis A</title>
          <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
            <count group_id="B2" value="299"/>
            <count group_id="B3" value="296"/>
            <count group_id="B4" value="199"/>
            <count group_id="B5" value="102"/>
            <count group_id="B6" value="1199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="199"/>
                    <measurement group_id="B5" value="102"/>
                    <measurement group_id="B6" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="1.91"/>
                    <measurement group_id="B2" value="14.5" spread="1.84"/>
                    <measurement group_id="B3" value="14.4" spread="1.88"/>
                    <measurement group_id="B4" value="14.3" spread="1.81"/>
                    <measurement group_id="B5" value="14.3" spread="1.93"/>
                    <measurement group_id="B6" value="14.4" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots</title>
        <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt;10 1/dil and post-vaccination titer ≥ 10 1/dil, or participants with pre-vaccination titer ≥ 10 1/dil and 4-fold increase from pre- to post-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Seroconversion to the JE CV vaccine antigens was assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1 subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>JE-CV GPO MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
          </group>
          <group group_id="O3">
            <title>JE-CV GPO MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots</title>
          <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt;10 1/dil and post-vaccination titer ≥ 10 1/dil, or participants with pre-vaccination titer ≥ 10 1/dil and 4-fold increase from pre- to post-vaccination.</description>
          <population>Seroconversion to the JE CV vaccine antigens was assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="286"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE CV Day 0 (≥10 1/dil; N=288, 290, 285, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="NA" lower_limit="0" upper_limit="0">Anti-Japanese encephalitis chimeric virus vaccine antibodies were not assayed in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV Day 28 (≥10 1/dil; N=288, 284, 283, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="262" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="267" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="185" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="NA" lower_limit="0" upper_limit="0">Anti-Japanese encephalitis chimeric virus vaccine antibodies were not assayed in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or Walter Reed Army Institute of Research (WRAIR) JE-CV</title>
        <description>Anti-Japanese Encephalitis Chimeric Virus antibodies were measured using the 50% plaque reduction neutralization test (PRNT50) assay.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Geometric mean titers against the JE CV antigens were assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1 subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>JE-CV GPO MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
          </group>
          <group group_id="O3">
            <title>JE-CV GPO MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or Walter Reed Army Institute of Research (WRAIR) JE-CV</title>
          <description>Anti-Japanese Encephalitis Chimeric Virus antibodies were measured using the 50% plaque reduction neutralization test (PRNT50) assay.</description>
          <population>Geometric mean titers against the JE CV antigens were assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="286"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti JE-CV Day 0 (N=288, 290, 285, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" lower_limit="5.06" upper_limit="5.29"/>
                    <measurement group_id="O2" value="5.08" lower_limit="4.99" upper_limit="5.17"/>
                    <measurement group_id="O3" value="5.19" lower_limit="5.02" upper_limit="5.37"/>
                    <measurement group_id="O4" value="5.09" lower_limit="4.95" upper_limit="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti JE CV Day 28 (N=288, 284, 283, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" lower_limit="179" upper_limit="252"/>
                    <measurement group_id="O2" value="167" lower_limit="138" upper_limit="202"/>
                    <measurement group_id="O3" value="188" lower_limit="156" upper_limit="226"/>
                    <measurement group_id="O4" value="212" lower_limit="168" upper_limit="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection to Japanese Encephalitis Chimeric Virus Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or WRAIR JE-CV</title>
        <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the PRNT50 assay. Seroprotection was defined as the proportion of subjects with a JE CV virus PRNT50 neutralizing antibody titer ≥10 1/dilution (dil).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Seroprotection against JE CV antigens was assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1</description>
          </group>
          <group group_id="O2">
            <title>JE-CV GPO MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
          </group>
          <group group_id="O3">
            <title>JE-CV GPO MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection to Japanese Encephalitis Chimeric Virus Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or WRAIR JE-CV</title>
          <description>Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the PRNT50 assay. Seroprotection was defined as the proportion of subjects with a JE CV virus PRNT50 neutralizing antibody titer ≥10 1/dilution (dil).</description>
          <population>Seroprotection against JE CV antigens was assessed in the participants who were vaccinated and completed all study defined activities, Per-Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="286"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE CV Day 0 (N=288, 290, 285, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="NA" lower_limit="0" upper_limit="0">Japanese encephalitis chimeric virus vaccine antibodies were not measured in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV Day 28 (N=288, 284, 283, 192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="269" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="276" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="190" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="NA" lower_limit="0" upper_limit="0">Japanese encephalitis chimeric virus vaccine antibodies were not measured in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Ratios Against the Japanese Encephalitis Chimeric Virus (JE-CV) Antigen Following Vaccination With One of the JE-CV by GPO MBP Lots or WRAIR JE-CV Vaccine</title>
        <description>Anti Japanese encephalitis chimeric virus antibodies were measured using the PRNT50 assay.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Geometric mean titers against the JE CV antigens were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1 subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>JE-CV MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE CV from GPO MBP Lot 2 subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>JE-CV MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE CV from GPO MBP Lot 3 subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE CV from Acambis at WRAIR subcutaneously</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received the Hepatitis vaccine intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Ratios Against the Japanese Encephalitis Chimeric Virus (JE-CV) Antigen Following Vaccination With One of the JE-CV by GPO MBP Lots or WRAIR JE-CV Vaccine</title>
          <description>Anti Japanese encephalitis chimeric virus antibodies were measured using the PRNT50 assay.</description>
          <population>Geometric mean titers against the JE CV antigens were assessed in the Per Protocol Analysis Set.</population>
          <units>Titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="286"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="34.6" upper_limit="48.7"/>
                    <measurement group_id="O2" value="32.9" lower_limit="27.3" upper_limit="39.8"/>
                    <measurement group_id="O3" value="36.6" lower_limit="30.3" upper_limit="44.1"/>
                    <measurement group_id="O4" value="42.2" lower_limit="33.3" upper_limit="53.3"/>
                    <measurement group_id="O5" value="NA">Participants in this group did not receive a Japanese encephalitis chimeric virus vaccine</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE- CV) by GPO MBP Lot or WRAIR JE-CV, or Hepatitis A Vaccine.</title>
        <description>Solicited injection site: Tenderness, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Tenderness, cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling ≥5 cm. Grade 3 systemic reactions: Fever, temperature &gt;39.5˚C; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal, &gt;3 hours; Drowsiness, sleeping most of the time or difficult to wake up; Appetite Lost, refuses ≥3 or most feeds/meals; and Irritability, inconsolable.</description>
        <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in the Safety Analysis Set. A participant randomized to receive JE CV GPO MBP Lot 1 vaccine, received JE CV GPO MBP Lot 3. For safety analysis, the participant was analyzed according to the actual vaccine received.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1 subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>JE-CV GPO MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
          </group>
          <group group_id="O3">
            <title>JE-CV GPO MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE- CV) by GPO MBP Lot or WRAIR JE-CV, or Hepatitis A Vaccine.</title>
          <description>Solicited injection site: Tenderness, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Tenderness, cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling ≥5 cm. Grade 3 systemic reactions: Fever, temperature &gt;39.5˚C; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal, &gt;3 hours; Drowsiness, sleeping most of the time or difficult to wake up; Appetite Lost, refuses ≥3 or most feeds/meals; and Irritability, inconsolable.</description>
          <population>Solicited injection site and systemic reactions were assessed in the Safety Analysis Set. A participant randomized to receive JE CV GPO MBP Lot 1 vaccine, received JE CV GPO MBP Lot 3. For safety analysis, the participant was analyzed according to the actual vaccine received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="59" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="67" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="59" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="18" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="63" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="87" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="54" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="26" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="62" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="64" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="57" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="39" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="54" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="53" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="38" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="71" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="74" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="57" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="79" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="79" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="28" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serological Status of Flavivirus Infection at Baseline (Before) Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) or Hepatitis A Vaccine.</title>
        <description>Flavivirus (FV) positive was defined as anti-JE against homologous virus strain ≥10 l/dil or anti dengue against at least one serotype ≥10 l/dil. FV negative was defined as anti-JE against homologous virus strain &lt;10 l/dil and anti-dengue against the 4 serotypes &lt;10 l/dilution.</description>
        <time_frame>Day 0 (pre-vaccination)</time_frame>
        <population>Serological status of Flavivirus infection was assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV GPO MBP (Lot 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1</description>
          </group>
          <group group_id="O2">
            <title>JE-CV GPO MBP (Lot 2)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
          </group>
          <group group_id="O3">
            <title>JE-CV GPO MBP (Lot 3)</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
          </group>
          <group group_id="O4">
            <title>JE-CV WRAIR</title>
            <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
          </group>
          <group group_id="O5">
            <title>Hepatitis A</title>
            <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Serological Status of Flavivirus Infection at Baseline (Before) Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) or Hepatitis A Vaccine.</title>
          <description>Flavivirus (FV) positive was defined as anti-JE against homologous virus strain ≥10 l/dil or anti dengue against at least one serotype ≥10 l/dil. FV negative was defined as anti-JE against homologous virus strain &lt;10 l/dil and anti-dengue against the 4 serotypes &lt;10 l/dilution.</description>
          <population>Serological status of Flavivirus infection was assessed in the Per-protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE CV/dengue FV positive (N=288,290,285,192,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="15" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="13" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV/dengue FV negative (N=288,290,285,192,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="266" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="249" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="176" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="84" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV (N=288, 290, 285, 192, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 1 (N=284, 289, 282, 192, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="28" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="14" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="13" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 2 (N=284, 289, 282, 192, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="11" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="12" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 3 (N=284, 289, 282, 192, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="27" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="12" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="11" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 4 (N=284, 289, 282, 192, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) data were collected from Day 0 (post-vaccination) up to Day 180 post-vaccination.</time_frame>
      <desc>The total (N) for solicited AEs in the table reflects participants for which diary cards were returned and with available data for the event during the period. A participant randomized to receive JE CV GPO MBP Lot 1 vaccine, received JE CV GPO MBP Lot 3. For safety analysis, the participant was analyzed according to the actual vaccine received.</desc>
      <group_list>
        <group group_id="E1">
          <title>JE-CV GPO MBP (Lot 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO MBP) Lot 1</description>
        </group>
        <group group_id="E2">
          <title>JE-CV GPO MBP (Lot 2)</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 2</description>
        </group>
        <group group_id="E3">
          <title>JE-CV GPO MBP (Lot 3)</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from GPO MBP Lot 3</description>
        </group>
        <group group_id="E4">
          <title>JE-CV WRAIR</title>
          <description>Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)</description>
        </group>
        <group group_id="E5">
          <title>Hepatitis A</title>
          <description>Participants 12 to 18 months of age received Hepatitis A vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Testicular yolk sac tumour stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="199"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="302"/>
                <counts group_id="E2" events="57" subjects_affected="57" subjects_at_risk="299"/>
                <counts group_id="E3" events="53" subjects_affected="53" subjects_at_risk="297"/>
                <counts group_id="E4" events="39" subjects_affected="39" subjects_at_risk="199"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Injection site tenderness</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="302"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="299"/>
                <counts group_id="E3" events="67" subjects_affected="67" subjects_at_risk="297"/>
                <counts group_id="E4" events="59" subjects_affected="59" subjects_at_risk="199"/>
                <counts group_id="E5" events="18" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="302"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="299"/>
                <counts group_id="E3" events="87" subjects_affected="87" subjects_at_risk="297"/>
                <counts group_id="E4" events="54" subjects_affected="54" subjects_at_risk="199"/>
                <counts group_id="E5" events="26" subjects_affected="26" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="299"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="302"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="299"/>
                <counts group_id="E3" events="64" subjects_affected="64" subjects_at_risk="297"/>
                <counts group_id="E4" events="48" subjects_affected="48" subjects_at_risk="199"/>
                <counts group_id="E5" events="21" subjects_affected="21" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="299"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="302"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="299"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="297"/>
                <counts group_id="E4" events="26" subjects_affected="21" subjects_at_risk="199"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="99" subjects_affected="84" subjects_at_risk="302"/>
                <counts group_id="E2" events="88" subjects_affected="78" subjects_at_risk="299"/>
                <counts group_id="E3" events="79" subjects_affected="72" subjects_at_risk="297"/>
                <counts group_id="E4" events="58" subjects_affected="52" subjects_at_risk="199"/>
                <counts group_id="E5" events="42" subjects_affected="36" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Lost</sub_title>
                <counts group_id="E1" events="82" subjects_affected="82" subjects_at_risk="302"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="299"/>
                <counts group_id="E3" events="74" subjects_affected="74" subjects_at_risk="297"/>
                <counts group_id="E4" events="57" subjects_affected="57" subjects_at_risk="199"/>
                <counts group_id="E5" events="27" subjects_affected="27" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="302"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="299"/>
                <counts group_id="E3" events="53" subjects_affected="53" subjects_at_risk="297"/>
                <counts group_id="E4" events="38" subjects_affected="38" subjects_at_risk="199"/>
                <counts group_id="E5" events="20" subjects_affected="20" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying Abnormal</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="302"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="299"/>
                <counts group_id="E3" events="50" subjects_affected="50" subjects_at_risk="297"/>
                <counts group_id="E4" events="41" subjects_affected="41" subjects_at_risk="199"/>
                <counts group_id="E5" events="21" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="302"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="299"/>
                <counts group_id="E3" events="79" subjects_affected="79" subjects_at_risk="297"/>
                <counts group_id="E4" events="65" subjects_affected="65" subjects_at_risk="199"/>
                <counts group_id="E5" events="28" subjects_affected="28" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

